CUE Cue Biopharma, Inc.

NASDAQ
$2.83

Cue Biopharma, Inc. (CUE) is expected to report earnings on February 15, 2027, after the market close. The consensus earnings estimate is a loss of $2.83 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -78.3% since its last earnings release on November 16, 2026.

Cue Biopharma Missed Consensus Estimates
Monday, November 16, 2026 · 4:48 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 15
Monday · 4:05 PM ET
Earnings Whisper
-
vs ($2.83)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.83

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Cue Biopharma, Inc.

Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts.

Sector

Healthcare

Charts powered in part by Lightweight Charts™ by TradingView.